Literature DB >> 10569295

Major bleeding after hospitalization for deep-venous thrombosis.

R H White1, R J Beyth, H Zhou, P S Romano.   

Abstract

PURPOSE: Most studies of oral anticoagulant-related bleeding have analyzed the incidence of adverse outcomes among patients with a variety of different conditions and without any comparison with a control group. We determined the incidence, time course, and risk factors associated with major bleeding after hospital discharge among patients with deep-vein thrombosis, and estimated the excess risk of bleeding associated with oral anticoagulant therapy.
METHODS: A total of 22,000 adults were hospitalized in California for 3 or more days with a diagnosis of deep-venous thrombosis between January 1, 1992, and September 30, 1994. We determined the risk factors associated with readmission for bleeding. We compared the incidence of readmission for bleeding with comparison cohorts of patients with pneumonia or cellulitis who were matched for age, gender, race, and length of hospital stay.
RESULTS: Of 21,250 patients with deep-venous thrombosis who were discharged without bleeding, 1.4% were readmitted for bleeding within 91 days; the rate was 2.7 times greater in the first 30 days than in the next 61 days. Risk factors for bleeding included hospitalization with gastrointestinal bleeding during the previous 18 months (relative hazard [RH] = 2.6, 95% confidence interval [CI]: 1.6 to 4.1), hospitalization with an alcohol-related diagnosis during the previous 18 months (RH = 2.6, 95% CI: 1.4 to 4.8), chronic renal disease (RH = 2.4, 95% CI: 1.4 to 4.2), female gender (RH = 1.7, 95% CI: 1.3 to 2.2), presence of a malignancy (RH = 1.6, 95% CI: 1.2 to 2.2), nonwhite race (RH = 1.6, 95% CI: 1.2 to 2.1), and age over 65 years (RH = 1.3, 95% CI: 1.0 to 1.7). Significantly more women (n = 40) had intracranial bleeding than men (n = 18, P = 0.02). In the comparison cohorts, the incidence of readmission for bleeding within 3 months of discharge was 0.7%, and the relative risk (RR) of readmission was greater in those with deep-venous thrombosis than in those with cellulitis (RR = 2.0, 95% CI: 1.6 to 2.5) or pneumonia (RR = 2.0, 95% CI: 1.7 to 2.5).
CONCLUSIONS: The incidence of rehospitalization for bleeding was greatest in the first 30 days after discharge, and was approximately twice that seen in patients hospitalized for cellulitis or pneumonia. Further studies are needed to determine why women and nonwhite patients are at increased risk for anticoagulant-related bleeding.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10569295     DOI: 10.1016/s0002-9343(99)00267-3

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  48 in total

1.  A pharmacokinetic-pharmacodynamic model for predicting the impact of CYP2C9 and VKORC1 polymorphisms on fluindione and acenocoumarol during induction therapy.

Authors:  Céline Verstuyft; Xavier Delavenne; Alexandra Rousseau; Annie Robert; Michel Tod; Bertrand Diquet; Martine Lebot; Patrice Jaillon; Laurent Becquemont
Journal:  Clin Pharmacokinet       Date:  2012-01-01       Impact factor: 6.447

2.  Cost effectiveness of dalteparin for preventing venous thromboembolism in abdominal surgery.

Authors:  Adrienne Heerey; Sanjeev Suri
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

3.  Clinical Benefit of American College of Chest Physicians versus European Society of Cardiology Guidelines for Stroke Prophylaxis in Atrial Fibrillation.

Authors:  Ambar A Andrade; Juan Li; Martha J Radford; David S Nilasena; Brian F Gage
Journal:  J Gen Intern Med       Date:  2015-02-10       Impact factor: 5.128

4.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Clive Kearon; Elie A Akl; Anthony J Comerota; Paolo Prandoni; Henri Bounameaux; Samuel Z Goldhaber; Michael E Nelson; Philip S Wells; Michael K Gould; Francesco Dentali; Mark Crowther; Susan R Kahn
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 5.  Optional inferior vena caval filters: where are we now?

Authors:  A N Keeling; T B Kinney; M J Lee
Journal:  Eur Radiol       Date:  2008-04-02       Impact factor: 5.315

Review 6.  Ethnic differences in cardiovascular drug response: potential contribution of pharmacogenetics.

Authors:  Julie A Johnson
Journal:  Circulation       Date:  2008-09-23       Impact factor: 29.690

7.  Effectiveness of warfarin among patients with cancer.

Authors:  Adam J Rose; Jeff P Sharman; Al Ozonoff; Lori E Henault; Elaine M Hylek
Journal:  J Gen Intern Med       Date:  2007-05-03       Impact factor: 5.128

8.  Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients.

Authors:  P A Lenzini; G R Grice; P E Milligan; M B Dowd; S Subherwal; E Deych; C S Eby; C R King; R M Porche-Sorbet; C V Murphy; R Marchand; E A Millican; R L Barrack; J C Clohisy; K Kronquist; S K Gatchel; B F Gage
Journal:  J Thromb Haemost       Date:  2008-07-24       Impact factor: 5.824

9.  Ginkgo and Warfarin Interaction in a Large Veterans Administration Population.

Authors:  Gregory J Stoddard; Melissa Archer; Laura Shane-McWhorter; Bruce E Bray; Doug F Redd; Joshua Proulx; Qing Zeng-Treitler
Journal:  AMIA Annu Symp Proc       Date:  2015-11-05

10.  Pharmacogenetics of anticoagulants.

Authors:  Anders Rane; Jonatan D Lindh
Journal:  Hum Genomics Proteomics       Date:  2010-09-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.